ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,163.85
0.70%
US Tech 100
17,526.60
0.62%
다우존스 지수
38,799.06
0.32%
Bitcoin
63,073.76
-1.45%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Lexaria Bioscience Corporation (LEXX)

  7. Lexaria Bioscience Corporation (LEXX) 뉴스

LEXX

Lexaria Bioscience (LEXX)

Lexaria Bioscience Corporation
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:LEXX
일자시간출처헤드라인심볼기업
2024/03/0620:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LEXXLexaria Bioscience Corporation
2024/03/0204:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
2024/02/1706:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
2024/02/1705:47Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LEXXLexaria Bioscience Corporation
2024/02/1620:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LEXXLexaria Bioscience Corporation
2024/02/1504:20Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
2024/02/1502:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
2024/01/3103:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/2914:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/2504:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/2503:33Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/1904:38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/1307:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LEXXLexaria Bioscience Corporation
2024/01/1122:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/1022:45InvestorsHub NewsWireGLP-1: Beyond Diabetes, a Blockbuster Horizon BeckonsNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/0922:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery PlatformNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/0822:45InvestorsHub NewsWireExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss DrugsNASDAQ:LEXXLexaria Bioscience Corporation
2024/01/0507:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
2023/12/1114:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXLexaria Bioscience Corporation
2023/12/0906:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LEXXLexaria Bioscience Corporation
2023/12/0106:14Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LEXXLexaria Bioscience Corporation
2023/11/2107:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LEXXLexaria Bioscience Corporation
2023/11/0402:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
2023/11/0202:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXLexaria Bioscience Corporation
2023/11/0121:45InvestorsHub NewsWireGet Ready for Next Generation of Diabetes, Weight-Management DrugsNASDAQ:LEXXLexaria Bioscience Corporation
2023/11/0121:30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceNASDAQ:LEXXLexaria Bioscience Corporation
2023/10/3121:31GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 DrugsNASDAQ:LEXXLexaria Bioscience Corporation
2023/10/3101:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXLexaria Bioscience Corporation
2023/10/3021:45InvestorsHub NewsWireCan Diabetes, Weight-Loss Drugs Get Even Better?NASDAQ:LEXXLexaria Bioscience Corporation
2023/10/1901:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
 검색 관련기사 보기:NASDAQ:LEXX

최근 히스토리

USOTC
BASFY
BASF (QX)
COIN
ETHUSD
Ethereum
AMEX
SPY
SPDR S&P 500
NYSE
AXP
American Express
SPI
SP500
S&P 500
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
AMEX
XLV
Health Care Select Sector
NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
COIN
SOLUSD
Solana
NASDAQ
MSFT
Microsoft
NASDAQ
TSLA
Tesla
NASDAQ
AMZN
Amazon.com
FX
USDJPY
US Dollar vs Yen
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유